Log in

NYSE:TEVA - Teva Pharmaceutical Industries Stock Price, Forecast & News

$7.56
-0.34 (-4.30 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$7.51
Now: $7.56
$7.81
50-Day Range
$6.69
MA: $10.61
$13.45
52-Week Range
$6.07
Now: $7.56
$15.92
Volume21.08 million shs
Average Volume24.11 million shs
Market Capitalization$8.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Read More
Teva Pharmaceutical Industries logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone972-3914-8171

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.89 billion
Cash Flow$3.72 per share
Book Value$13.79 per share

Profitability

Net Income$-998,000,000.00

Miscellaneous

Employees40,039
Outstanding Shares1,092,190,000
Market Cap$8.26 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.


Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

How has Teva Pharmaceutical Industries' stock been impacted by COVID-19 (Coronavirus)?

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TEVA shares have decreased by 16.1% and is now trading at $7.56. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Teva Pharmaceutical Industries?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 4 sell ratings, 14 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Teva Pharmaceutical Industries.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Teva Pharmaceutical Industries.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced its quarterly earnings data on Wednesday, February, 12th. The company reported $0.62 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.61 by $0.01. The business earned $4.47 billion during the quarter, compared to analysts' expectations of $4.35 billion. Teva Pharmaceutical Industries had a negative net margin of 5.75% and a positive return on equity of 16.57%. The firm's revenue was up 1.1% on a year-over-year basis. During the same period last year, the business earned $0.53 earnings per share. View Teva Pharmaceutical Industries' earnings history.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY20 earnings guidance on Wednesday, February, 12th. The company provided EPS guidance of $2.30-2.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.47. The company issued revenue guidance of $16.6-17.0 billion, compared to the consensus revenue estimate of $17.14 billion.

What price target have analysts set for TEVA?

24 brokerages have issued 12-month price targets for Teva Pharmaceutical Industries' shares. Their forecasts range from $7.00 to $16.00. On average, they anticipate Teva Pharmaceutical Industries' stock price to reach $11.65 in the next twelve months. This suggests a possible upside of 54.1% from the stock's current price. View analysts' price targets for Teva Pharmaceutical Industries.

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

Media coverage about TEVA stock has trended somewhat negative this week, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutTeva Pharmaceutical Industries.

Who are some of Teva Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Bank of America (BAC), Intel (INTC), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Cisco Systems (CSCO).

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the following people:
  • Mr. Kåre Schultz, Pres, CEO & Director (Age 58)
  • Mr. Michael McClellan, Exec. VP & CFO (Age 48)
  • Mr. Mark Sabag, Exec. VP of Global HR (Age 48)
  • Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 61)
  • Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 57)

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by many different retail and institutional investors. Top institutional investors include Capital Research Global Investors (11.99%), Franklin Resources Inc. (1.82%), Franklin Resources Inc. (1.82%), Migdal Insurance & Financial Holdings Ltd. (1.16%), Norges Bank (0.78%) and Menora Mivtachim Holdings LTD. (0.77%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Roberto Mignone, Sol J Barer and Sven Dethlefs. View institutional ownership trends for Teva Pharmaceutical Industries.

Which institutional investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Franklin Resources Inc., Renaissance Technologies LLC, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Commerzbank Aktiengesellschaft FI, Acadian Asset Management LLC, Caisse DE Depot ET Placement DU Quebec, and Nuveen Asset Management LLC. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, and Richard Daniell. View insider buying and selling activity for Teva Pharmaceutical Industries.

Which institutional investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Menora Mivtachim Holdings LTD., Migdal Insurance & Financial Holdings Ltd., Harel Insurance Investments & Financial Services Ltd., Phoenix Holdings Ltd., Banco Bilbao Vizcaya Argentaria S.A., Beck Mack & Oliver LLC, and Van ECK Associates Corp. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone, Sol J Barer, and Sven Dethlefs. View insider buying and selling activity for Teva Pharmaceutical Industries.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $7.56.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $8.26 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 40,039 workers across the globe. View additional information about Teva Pharmaceutical Industries.

What is Teva Pharmaceutical Industries' official website?

The official website for Teva Pharmaceutical Industries is http://www.tevapharm.com/.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]


MarketBeat Community Rating for Teva Pharmaceutical Industries (NYSE TEVA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  1,269 (Vote Outperform)
Underperform Votes:  1,171 (Vote Underperform)
Total Votes:  2,440
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel